Purpose: To evaluate the validity of the Gleason score after neoadjuvant hormonal treatment as predictor of disease-specific mortality after radical prostatectomy. Patients and Methods: A total of 2,880 patients with a complete data set and a mean follow-up of 10.3 years were studied; 425 of them (15%) had a history of hormonal treatment prior to surgery. The cumulative incidence of deaths from prostate cancer was determined by univariate and multivariate competing risk analysis. Cox proportional hazard models for competing risks were used to study combined effects of the variables on prostate cancer-specific mortality. Results: A higher portion of specimens with a history of neoadjuvant hormonal treatment were assigned Gleason scores of 8-10 (28 vs. 17%, p < 0.0001). The mortality curves in the Gleason score strata <8 vs. 8-10 were at large congruent in patients with and without neoadjuvant hormonal treatment. In patients with neoadjuvant hormonal treatment, a Gleason score of 8-10 was an independent predictor of prostate cancer-specific mortality; the hazard ratio was, however, somewhat lower than in patients without neoadjuvant hormonal treatment. Conclusion: This study suggests that the prognostic value of the post-radical prostatectomy Gleason score is not meaningfully jeopardized by heterogeneous neoadjuvant hormonal treatment in a routine clinical setting.

Keywords:
Hormonal treatment, Neoadjuvant, Gleason score , Health outcomes research, Prostate cancer, Radical prostatectomy, Prognostic factors 
1.
Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996;20:86-93.
2.
Bentley G, Dey J, Sakr WA, Wood DP Jr, Pontes JE, Grignon DJ: Significance of the Gleason scoring system after neoadjuvant hormonal therapy. Mol Urol 2000;4:125; discussion 131.
3.
Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL: Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002;26:1400-1413.
4.
Deutsche Gesellschaft für Urologie e. V.: Konsultationsfassung. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der Verschiedenen Stadien des Prostatakarzinoms. AWMF-Register-Nummer (034/022OL) Version 2.2-2. Aktualisierung, 2014. http://www.dgu.de/fileadmin/MDB/PDF/konsultationsfassung-leitlinie-prostatakarzinom.pdf (visited August 22, 2015).
5.
Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A; Lupron Depot Neoadjuvant Prostate Cancer Study Group: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167:112-116.
6.
Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P: Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol 2010;57:1030-1038.
7.
Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP 3rd, Crawford ED, Thompson IM Jr, Klein EA: Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest oncology group study 9109. Urology 2012;79:633-637.
8.
Mottet N, Bellmunt J, Briers E, van den Bergh RCN, Bolla M, van Casteren NJ, Cornford P, Culine S, Joniau S, Lam T, Mason MD, Matveev V, van der Poel H, van der Kwast TH, Rouvière O, Wiegel T: EAU Guidelines on Prostate Cancer. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf (visited August 22, 2015).
9.
Fumadó L, Cecchini L, Juanpere N, Ubré A, Lorente JA, Alcaraz A: Twelve core template prostate biopsy is an unreliable tool to select patients eligible for focal therapy. Urol Int 2015;95:197-202.
10.
Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K: The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy. Urol Int 2014;93:289-295.
11.
Winter A, Kneib T, Rohde M, Henke RP, Wawroschek F: First nomogram predicting the probability of lymph node involvement in prostate cancer patients undergoing radioisotope guided sentinel lymph node dissection. Urol Int 2015, Epub ahead of print.
12.
Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
13.
Pintilie M: Competing Risks: A Practical Perspective. Chichester, England, Hoboken, John Wiley & Sons, 2006, pp 195-207.
14.
Parmar MKB, Machin D: Survival Analysis. A Practical Approach. Chichester, England, John Wiley & Sons, 1996, pp 75-87.
15.
Gofrit ON, Zorn KC, Steinberg GD, Zagaja GP, Shalhav AL: The will rogers phenomenon in urological oncology. J Urol 2008;179:28-33.
16.
Goldenberg SL, LaBianca SE, Gleave ME: Neoadjuvant androgen withdrawal therapy before radical prostatectomy. Curr Oncol 2004;7(suppl 1):S5-S8.
17.
Selli C, Montironi R, Bono A, Pagano F, Zattoni F, Manganelli A, Selvaggi FP, Comeri G, Fiaccavento G, Guazzieri S, Lembo A, Cosciani-Cunico S, Potenzoni D, Muto G, Mazzucchelli R, Santinelli A; PROSIT Study Group: Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 2002;55:508-513.
18.
Hu J, Xu H, Zhu W, Wu F, Wang J, Ding Q, Jiang H: Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients. World J Surg Oncol 2015;13:73.
19.
Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D, Persad R, Koupparis A: The status of surgery in the management of high-risk prostate cancer. Nat Rev Urol 2014;11:342-351.
20.
Brierley JD, Greene FL, Sobin LH, Wittekind C: The ‘y' symbol: an important classification tool for neoadjuvant cancer treatment. Cancer 2006;106:2526-2527.
21.
Sobin LH, Gospodarowicz MK, Wittekind C; International Union Against Cancer: TNM Classification of Malignant Tumours, ed 7, 2009. Chichester, West Sussex, UK, Hoboken, Wiley-Blackwell, 2010, pp 243-248.
22.
Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-506; discussion 506-507.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.